We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's Shingles Vaccine Shingrix Gets Approval in China
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) announced on May 23 that its vaccine Shingrix has been approved in China for the prevention of shingles (herpes zoster) in older patients (aged 50 years or older).
The company plans to launch the vaccine in China in several phases starting 2020.
Notably, Shingrix is already approved in the United States and Canada for preventing shingles. In March 2019, the vaccine was approved in Europe and Japan. The candidate is also approved in Australia for the same indication.
Glaxo’s shares have outperformed the industry so far this year. The stock has increased 5.2% compared with the industry’s 0.7% rise.
The approval of Shingrix in China was based on data from a clinical trial program comprising two phase III studies — ZOE-50 and ZOE-70. The studies evaluated the safety, efficacy and immunogenicity of the candidate in more than 38,000 individuals. Significantly, Shingrix is the only shingles vaccine to achieve 90% efficacy or more in adults aged 50 and above.
Shingrix has driven sales of Glaxo’s Vaccine segment for the past few quarters on strong demand. Sales of the vaccine increased more than 60% sequentially in the first quarter of 2019, crossing $450 million (£357 million) globally.
The encouraging performance of the vaccine is expected to continue on strong demand in the United States as well as approval and potential launch in new geographies. Shingrix enjoys preferential recommendation from the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (“ACIP”). In 2017, the ACIP recommended the preferential use of Shingrix for the prevention of shingles over Merck’s (MRK - Free Report) Zostavax.
Shingrix is also being evaluated in immuno-compromised patient populations, including solid and hematological cancer patients, hematopoietic stem cell and renal transplant recipients and HIV infected people.
Per the company’s press release, around one in three people worldwide is vulnerable to develop shingles in a lifetime with increasing age. Additionally, 30% of shingles patients develop PNH. Hence, the potential market opportunity to prevent this serious life-threatening disease is huge.
Roche's earnings estimates have increased from $2.35 to $2.40 for 2019 and from $2037 to $2.40 for 2020 over the past 60 days. The stock has increased 6% so far this year..
AbbVie’s earnings estimates have increased from $8.68 to $8.81 for 2019 and from $9.26 to $9.38 for 2020 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Glaxo's Shingles Vaccine Shingrix Gets Approval in China
GlaxoSmithKline plc (GSK - Free Report) announced on May 23 that its vaccine Shingrix has been approved in China for the prevention of shingles (herpes zoster) in older patients (aged 50 years or older).
The company plans to launch the vaccine in China in several phases starting 2020.
Notably, Shingrix is already approved in the United States and Canada for preventing shingles. In March 2019, the vaccine was approved in Europe and Japan. The candidate is also approved in Australia for the same indication.
Glaxo’s shares have outperformed the industry so far this year. The stock has increased 5.2% compared with the industry’s 0.7% rise.
The approval of Shingrix in China was based on data from a clinical trial program comprising two phase III studies — ZOE-50 and ZOE-70. The studies evaluated the safety, efficacy and immunogenicity of the candidate in more than 38,000 individuals. Significantly, Shingrix is the only shingles vaccine to achieve 90% efficacy or more in adults aged 50 and above.
Shingrix has driven sales of Glaxo’s Vaccine segment for the past few quarters on strong demand. Sales of the vaccine increased more than 60% sequentially in the first quarter of 2019, crossing $450 million (£357 million) globally.
The encouraging performance of the vaccine is expected to continue on strong demand in the United States as well as approval and potential launch in new geographies. Shingrix enjoys preferential recommendation from the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (“ACIP”). In 2017, the ACIP recommended the preferential use of Shingrix for the prevention of shingles over Merck’s (MRK - Free Report) Zostavax.
Shingrix is also being evaluated in immuno-compromised patient populations, including solid and hematological cancer patients, hematopoietic stem cell and renal transplant recipients and HIV infected people.
Per the company’s press release, around one in three people worldwide is vulnerable to develop shingles in a lifetime with increasing age. Additionally, 30% of shingles patients develop PNH. Hence, the potential market opportunity to prevent this serious life-threatening disease is huge.
GlaxoSmithKline plc Price
GlaxoSmithKline plc price | GlaxoSmithKline plc Quote
Zacks Rank & Stocks to Consider
Glaxo currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the same sector include Roche Holding AG (RHHBY - Free Report) and AbbVie Inc. (ABBV - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Roche's earnings estimates have increased from $2.35 to $2.40 for 2019 and from $2037 to $2.40 for 2020 over the past 60 days. The stock has increased 6% so far this year..
AbbVie’s earnings estimates have increased from $8.68 to $8.81 for 2019 and from $9.26 to $9.38 for 2020 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>